Guizhou Sanli Pharmaceutical Co.,Ltd

SHSE:603439 Stock Report

Market Cap: CN¥4.9b

Guizhou Sanli PharmaceuticalLtd Future Growth

Future criteria checks 4/6

Guizhou Sanli PharmaceuticalLtd is forecast to grow earnings and revenue by 21.5% and 22.8% per annum respectively. EPS is expected to grow by 21.7% per annum. Return on equity is forecast to be 19.4% in 3 years.

Key information

21.5%

Earnings growth rate

21.7%

EPS growth rate

Pharmaceuticals earnings growth19.5%
Revenue growth rate22.8%
Future return on equity19.4%
Analyst coverage

Low

Last updated30 Aug 2024

Recent future growth updates

No updates

Recent updates

Little Excitement Around Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Earnings

Aug 25
Little Excitement Around Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Earnings

Is Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Trading At A 20% Discount?

Aug 03
Is Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Trading At A 20% Discount?

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Apr 23
Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Mar 25
Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 06
Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Earnings and Revenue Growth Forecasts

SHSE:603439 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,545522N/A4823
12/31/20252,976429N/A5663
12/31/20242,456343N/A683
6/30/20241,925309149206N/A
3/31/20241,708294205284N/A
12/31/20231,635293168277N/A
9/30/20231,461256215334N/A
6/30/20231,402238200309N/A
3/31/20231,39223281236N/A
12/31/20221,201201173293N/A
9/30/20221,03514442147N/A
6/30/202299214754148N/A
3/31/2022968153165182N/A
12/31/2021939152129155N/A
9/30/2021881157125174N/A
6/30/202172511734103N/A
3/31/20216129236101N/A
12/31/2020630941263N/A
9/30/2020676885178N/A
6/30/2020818124121125N/A
3/31/20208881378592N/A
12/31/2019884133108116N/A
6/30/20197711089197N/A
3/31/2019754104111112N/A
12/31/20187221107475N/A
6/30/20187001206567N/A
3/31/2018665106N/A46N/A
12/31/201763888N/A57N/A
9/30/201759777N/A43N/A
6/30/201755666N/A28N/A
3/31/201750168N/A19N/A
12/31/201651575N/A35N/A
9/30/201646469N/A30N/A
6/30/201641463N/A26N/A
3/31/201638658N/A29N/A
12/31/201535953N/A33N/A
9/30/201532546N/A28N/A
6/30/201529140N/A23N/A
3/31/201527934N/A12N/A
12/31/201426729N/A1N/A
12/31/201315919N/A30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603439's forecast earnings growth (21.5% per year) is above the savings rate (2.9%).

Earnings vs Market: 603439's earnings (21.5% per year) are forecast to grow slower than the CN market (23.1% per year).

High Growth Earnings: 603439's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603439's revenue (22.8% per year) is forecast to grow faster than the CN market (13.3% per year).

High Growth Revenue: 603439's revenue (22.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603439's Return on Equity is forecast to be low in 3 years time (19.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y